 | • レポートコード：MRC2Q12-19386 • 出版社/出版日：QYResearch / 2022年12月 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥725,200 (USD4,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,450,400 (USD9,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、組換えインスリン類似体のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。 組換えインスリン類似体のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 組換えインスリン類似体の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 組換えインスリン類似体のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。 生産面において、本レポートは2017年から2022年までの組換えインスリン類似体の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の組換えインスリン類似体の売上および2028年までの予測に焦点を当てています。 組換えインスリン類似体のグローバル主要企業には、Novo Nordisk A/S、Eli Lilly and Company、Sanofi、Gan & Lee Pharmaceuticals Co., Ltd、The United Laboratories International Holdings Limited、Tonghua Dongbao Pharmaceutical Co., Ltdなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx％の市場シェアを占めています。 組換えインスリン類似体市場は、タイプとアプリケーションによって区分されます。世界の組換えインスリン類似体市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年～2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。 【タイプ別セグメント】 即効性、中効性、持続性、超持続性 【アプリケーション別セグメント】 1型糖尿病、2型糖尿病 【掲載地域】 北米：アメリカ、カナダ ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア アジア太平洋：日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア 中南米：メキシコ、ブラジル、アルゼンチン 中東・アフリカ：トルコ、サウジアラビア、UAE 【目次（一部）】 ・調査の範囲 - 組換えインスリン類似体製品概要 - タイプ別市場（即効性、中効性、持続性、超持続性） - アプリケーション別市場（1型糖尿病、2型糖尿病） - 調査の目的 ・エグゼクティブサマリー - 世界の組換えインスリン類似体販売量予測2017-2028 - 世界の組換えインスリン類似体売上予測2017-2028 - 組換えインスリン類似体の地域別販売量 - 組換えインスリン類似体の地域別売上 - 北米市場 - ヨーロッパ市場 - アジア太平洋市場 - 中南米市場 - 中東・アフリカ市場 ・メーカーの競争状況 - 主要メーカー別組換えインスリン類似体販売量 - 主要メーカー別組換えインスリン類似体売上 - 主要メーカー別組換えインスリン類似体価格 - 競争状況の分析 - 企業M&A動向 ・タイプ別市場規模（即効性、中効性、持続性、超持続性） - 組換えインスリン類似体のタイプ別販売量 - 組換えインスリン類似体のタイプ別売上 - 組換えインスリン類似体のタイプ別価格 ・アプリケーション別市場規模（1型糖尿病、2型糖尿病） - 組換えインスリン類似体のアプリケーション別販売量 - 組換えインスリン類似体のアプリケーション別売上 - 組換えインスリン類似体のアプリケーション別価格 ・北米市場 - 北米の組換えインスリン類似体市場規模（タイプ別、アプリケーション別） - 主要国別の組換えインスリン類似体市場規模（アメリカ、カナダ） ・ヨーロッパ市場 - ヨーロッパの組換えインスリン類似体市場規模（タイプ別、アプリケーション別） - 主要国別の組換えインスリン類似体市場規模（ドイツ、フランス、イギリス、イタリア、ロシア） ・アジア太平洋市場 - アジア太平洋の組換えインスリン類似体市場規模（タイプ別、アプリケーション別） - 主要国別の組換えインスリン類似体市場規模（日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア） ・中南米市場 - 中南米の組換えインスリン類似体市場規模（タイプ別、アプリケーション別） - 主要国別の組換えインスリン類似体市場規模（メキシコ、ブラジル、アルゼンチン） ・中東・アフリカ市場 - 中東・アフリカの組換えインスリン類似体市場規模（タイプ別、アプリケーション別） - 主要国別の組換えインスリン類似体市場規模（トルコ、サウジアラビア） ・企業情報 Novo Nordisk A/S、Eli Lilly and Company、Sanofi、Gan & Lee Pharmaceuticals Co., Ltd、The United Laboratories International Holdings Limited、Tonghua Dongbao Pharmaceutical Co., Ltd ・産業チェーン及び販売チャネル分析 - 組換えインスリン類似体の産業チェーン分析 - 組換えインスリン類似体の原材料 - 組換えインスリン類似体の生産プロセス - 組換えインスリン類似体の販売及びマーケティング - 組換えインスリン類似体の主要顧客 ・マーケットドライバー、機会、課題、リスク要因分析 - 組換えインスリン類似体の産業動向 - 組換えインスリン類似体のマーケットドライバー - 組換えインスリン類似体の課題 - 組換えインスリン類似体の阻害要因 ・主な調査結果 |
Recombinant insulin analogues are not easy to cause heterogenous allergic reaction in patients, with small side effects; It can simulate the physiological insulin secretion curve of human body, accurately adjust the blood glucose concentration of human body, reduce the risk of hypoglycemia, and further improve the safety and effectiveness.
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Product Name estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Recombinant Insulin Analogue is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Recombinant Insulin Analogue is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Recombinant Insulin Analogue is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key manufacturers of Recombinant Insulin Analogue include Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Gan & Lee Pharmaceuticals Co., Ltd, The United Laboratories International Holdings Limited and Tonghua Dongbao Pharmaceutical Co., Ltd, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Recombinant Insulin Analogue manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Recombinant Insulin Analogue market. Further, it explains the major drivers and regional dynamics of the global Recombinant Insulin Analogue market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable sales, revenue, price, market share and rank data of the manufacturers for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Novo Nordisk A/S
Eli Lilly and Company
Sanofi
Gan & Lee Pharmaceuticals Co., Ltd
The United Laboratories International Holdings Limited
Tonghua Dongbao Pharmaceutical Co., Ltd
Market Segments
This report has explored the key segments: by Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides sales, revenue and average price forecast data by type and by application segments based on sales, price, and value for the period 2017-2028.
Recombinant Insulin Analogue Segment by Type
Quick-Acting
Medium Effect
Long-Lasting
Super Long-Acting
Recombinant Insulin Analogue Segment by Application
Type 1 Diabetes
Type 2 Diabetes
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value and sales data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Recombinant Insulin Analogue market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Recombinant Insulin Analogue, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Recombinant Insulin Analogue, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Recombinant Insulin Analogue, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Recombinant Insulin Analogue sales, revenue, market share and industry ranking of main manufacturers, data from 2017 to 2022. Identification of the major stakeholders in the global Recombinant Insulin Analogue market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, sales, revenue, and price, from 2017 to 2028. Evaluation and forecast the market size for Recombinant Insulin Analogue sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Gan & Lee Pharmaceuticals Co., Ltd, The United Laboratories International Holdings Limited and Tonghua Dongbao Pharmaceutical Co., Ltd, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Recombinant Insulin Analogue in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Recombinant Insulin Analogue manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, sales and revenue for each segment.
Chapter 7: Europe by type, by application and by country, sales and revenue for each segment.
Chapter 8: Asia Pacific by type, by application and by country, sales and revenue for each segment.
Chapter 9: Latin America by type, by application and by country, sales and revenue for each segment.
Chapter 10: Middle East and Africa by type, by application and by country, sales and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Recombinant Insulin Analogue sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.
1 Study Coverage
1.1 Recombinant Insulin Analogue Product Introduction
1.2 Market by Type
1.2.1 Global Recombinant Insulin Analogue Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Quick-Acting
1.2.3 Medium Effect
1.2.4 Long-Lasting
1.2.5 Super Long-Acting
1.3 Market by Application
1.3.1 Global Recombinant Insulin Analogue Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Type 1 Diabetes
1.3.3 Type 2 Diabetes
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Recombinant Insulin Analogue Sales Estimates and Forecasts 2017-2028
2.2 Global Recombinant Insulin Analogue Revenue Estimates and Forecasts 2017-2028
2.3 Global Recombinant Insulin Analogue Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Recombinant Insulin Analogue Sales by Region
2.4.1 Global Recombinant Insulin Analogue Sales by Region (2017-2022)
2.4.2 Global Sales Recombinant Insulin Analogue by Region (2023-2028)
2.5 Global Recombinant Insulin Analogue Revenue by Region
2.5.1 Global Recombinant Insulin Analogue Revenue by Region (2017-2022)
2.5.2 Global Recombinant Insulin Analogue Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Recombinant Insulin Analogue Sales by Manufacturers
3.1.1 Global Top Recombinant Insulin Analogue Manufacturers by Sales (2017-2022)
3.1.2 Global Recombinant Insulin Analogue Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Recombinant Insulin Analogue in 2021
3.2 Global Recombinant Insulin Analogue Revenue by Manufacturers
3.2.1 Global Recombinant Insulin Analogue Revenue by Manufacturers (2017-2022)
3.2.2 Global Recombinant Insulin Analogue Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Recombinant Insulin Analogue Revenue in 2021
3.3 Global Recombinant Insulin Analogue Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Recombinant Insulin Analogue Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Recombinant Insulin Analogue Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Recombinant Insulin Analogue Sales by Type
4.1.1 Global Recombinant Insulin Analogue Historical Sales by Type (2017-2022)
4.1.2 Global Recombinant Insulin Analogue Forecasted Sales by Type (2023-2028)
4.1.3 Global Recombinant Insulin Analogue Sales Market Share by Type (2017-2028)
4.2 Global Recombinant Insulin Analogue Revenue by Type
4.2.1 Global Recombinant Insulin Analogue Historical Revenue by Type (2017-2022)
4.2.2 Global Recombinant Insulin Analogue Forecasted Revenue by Type (2023-2028)
4.2.3 Global Recombinant Insulin Analogue Revenue Market Share by Type (2017-2028)
4.3 Global Recombinant Insulin Analogue Price by Type
4.3.1 Global Recombinant Insulin Analogue Price by Type (2017-2022)
4.3.2 Global Recombinant Insulin Analogue Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Recombinant Insulin Analogue Sales by Application
5.1.1 Global Recombinant Insulin Analogue Historical Sales by Application (2017-2022)
5.1.2 Global Recombinant Insulin Analogue Forecasted Sales by Application (2023-2028)
5.1.3 Global Recombinant Insulin Analogue Sales Market Share by Application (2017-2028)
5.2 Global Recombinant Insulin Analogue Revenue by Application
5.2.1 Global Recombinant Insulin Analogue Historical Revenue by Application (2017-2022)
5.2.2 Global Recombinant Insulin Analogue Forecasted Revenue by Application (2023-2028)
5.2.3 Global Recombinant Insulin Analogue Revenue Market Share by Application (2017-2028)
5.3 Global Recombinant Insulin Analogue Price by Application
5.3.1 Global Recombinant Insulin Analogue Price by Application (2017-2022)
5.3.2 Global Recombinant Insulin Analogue Price Forecast by Application (2023-2028)
6 North America
6.1 North America Recombinant Insulin Analogue Market Size by Type
6.1.1 North America Recombinant Insulin Analogue Sales by Type (2017-2028)
6.1.2 North America Recombinant Insulin Analogue Revenue by Type (2017-2028)
6.2 North America Recombinant Insulin Analogue Market Size by Application
6.2.1 North America Recombinant Insulin Analogue Sales by Application (2017-2028)
6.2.2 North America Recombinant Insulin Analogue Revenue by Application (2017-2028)
6.3 North America Recombinant Insulin Analogue Market Size by Country
6.3.1 North America Recombinant Insulin Analogue Sales by Country (2017-2028)
6.3.2 North America Recombinant Insulin Analogue Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Recombinant Insulin Analogue Market Size by Type
7.1.1 Europe Recombinant Insulin Analogue Sales by Type (2017-2028)
7.1.2 Europe Recombinant Insulin Analogue Revenue by Type (2017-2028)
7.2 Europe Recombinant Insulin Analogue Market Size by Application
7.2.1 Europe Recombinant Insulin Analogue Sales by Application (2017-2028)
7.2.2 Europe Recombinant Insulin Analogue Revenue by Application (2017-2028)
7.3 Europe Recombinant Insulin Analogue Market Size by Country
7.3.1 Europe Recombinant Insulin Analogue Sales by Country (2017-2028)
7.3.2 Europe Recombinant Insulin Analogue Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Recombinant Insulin Analogue Market Size by Type
8.1.1 Asia Pacific Recombinant Insulin Analogue Sales by Type (2017-2028)
8.1.2 Asia Pacific Recombinant Insulin Analogue Revenue by Type (2017-2028)
8.2 Asia Pacific Recombinant Insulin Analogue Market Size by Application
8.2.1 Asia Pacific Recombinant Insulin Analogue Sales by Application (2017-2028)
8.2.2 Asia Pacific Recombinant Insulin Analogue Revenue by Application (2017-2028)
8.3 Asia Pacific Recombinant Insulin Analogue Market Size by Region
8.3.1 Asia Pacific Recombinant Insulin Analogue Sales by Region (2017-2028)
8.3.2 Asia Pacific Recombinant Insulin Analogue Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Recombinant Insulin Analogue Market Size by Type
9.1.1 Latin America Recombinant Insulin Analogue Sales by Type (2017-2028)
9.1.2 Latin America Recombinant Insulin Analogue Revenue by Type (2017-2028)
9.2 Latin America Recombinant Insulin Analogue Market Size by Application
9.2.1 Latin America Recombinant Insulin Analogue Sales by Application (2017-2028)
9.2.2 Latin America Recombinant Insulin Analogue Revenue by Application (2017-2028)
9.3 Latin America Recombinant Insulin Analogue Market Size by Country
9.3.1 Latin America Recombinant Insulin Analogue Sales by Country (2017-2028)
9.3.2 Latin America Recombinant Insulin Analogue Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
9.3.6 Colombia
10 Middle East and Africa
10.1 Middle East and Africa Recombinant Insulin Analogue Market Size by Type
10.1.1 Middle East and Africa Recombinant Insulin Analogue Sales by Type (2017-2028)
10.1.2 Middle East and Africa Recombinant Insulin Analogue Revenue by Type (2017-2028)
10.2 Middle East and Africa Recombinant Insulin Analogue Market Size by Application
10.2.1 Middle East and Africa Recombinant Insulin Analogue Sales by Application (2017-2028)
10.2.2 Middle East and Africa Recombinant Insulin Analogue Revenue by Application (2017-2028)
10.3 Middle East and Africa Recombinant Insulin Analogue Market Size by Country
10.3.1 Middle East and Africa Recombinant Insulin Analogue Sales by Country (2017-2028)
10.3.2 Middle East and Africa Recombinant Insulin Analogue Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Novo Nordisk A/S
11.1.1 Novo Nordisk A/S Corporation Information
11.1.2 Novo Nordisk A/S Overview
11.1.3 Novo Nordisk A/S Recombinant Insulin Analogue Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Novo Nordisk A/S Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Novo Nordisk A/S Recent Developments
11.2 Eli Lilly and Company
11.2.1 Eli Lilly and Company Corporation Information
11.2.2 Eli Lilly and Company Overview
11.2.3 Eli Lilly and Company Recombinant Insulin Analogue Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Eli Lilly and Company Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Eli Lilly and Company Recent Developments
11.3 Sanofi
11.3.1 Sanofi Corporation Information
11.3.2 Sanofi Overview
11.3.3 Sanofi Recombinant Insulin Analogue Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Sanofi Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Sanofi Recent Developments
11.4 Gan & Lee Pharmaceuticals Co., Ltd
11.4.1 Gan & Lee Pharmaceuticals Co., Ltd Corporation Information
11.4.2 Gan & Lee Pharmaceuticals Co., Ltd Overview
11.4.3 Gan & Lee Pharmaceuticals Co., Ltd Recombinant Insulin Analogue Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 Gan & Lee Pharmaceuticals Co., Ltd Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Gan & Lee Pharmaceuticals Co., Ltd Recent Developments
11.5 The United Laboratories International Holdings Limited
11.5.1 The United Laboratories International Holdings Limited Corporation Information
11.5.2 The United Laboratories International Holdings Limited Overview
11.5.3 The United Laboratories International Holdings Limited Recombinant Insulin Analogue Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 The United Laboratories International Holdings Limited Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 The United Laboratories International Holdings Limited Recent Developments
11.6 Tonghua Dongbao Pharmaceutical Co., Ltd
11.6.1 Tonghua Dongbao Pharmaceutical Co., Ltd Corporation Information
11.6.2 Tonghua Dongbao Pharmaceutical Co., Ltd Overview
11.6.3 Tonghua Dongbao Pharmaceutical Co., Ltd Recombinant Insulin Analogue Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 Tonghua Dongbao Pharmaceutical Co., Ltd Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Tonghua Dongbao Pharmaceutical Co., Ltd Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Recombinant Insulin Analogue Industry Chain Analysis
12.2 Recombinant Insulin Analogue Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Recombinant Insulin Analogue Production Mode & Process
12.4 Recombinant Insulin Analogue Sales and Marketing
12.4.1 Recombinant Insulin Analogue Sales Channels
12.4.2 Recombinant Insulin Analogue Distributors
12.5 Recombinant Insulin Analogue Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Recombinant Insulin Analogue Industry Trends
13.2 Recombinant Insulin Analogue Market Drivers
13.3 Recombinant Insulin Analogue Market Challenges
13.4 Recombinant Insulin Analogue Market Restraints
14 Key Findings in The Global Recombinant Insulin Analogue Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer